| Cash Flow | 2025-09-30 |
|---|---|
| Effect of exchange rate changes on cash | 269 |
| Net loss | -6,407 |
| Depreciation and amortization | 66 |
| Unrealized loss on foreign currency remeasurement | -13 |
| Stock-based compensation expense | 2,626 |
| Prepaid expenses and other current assets | -299 |
| R&d tax incentive | 364 |
| Trade and other payables | -5,396 |
| Net cash used in operating activities | -9,163 |
| Purchase of property, plant and equipment | 2 |
| Investment of joint venture | 40 |
| Net cash used in investing activities | -42 |
| Proceeds from share issuance | 69,465 |
| Share issuance costs | 2,288 |
| Net cash provided by financing activities | 67,177 |
| Net increase/(decrease) in cash and cash equivalents | 57,972 |
| Cash and cash equivalents at beginning of period | 15,039 |
| Cash and cash equivalents at end of period | 73,280 |
Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc. (IXHL)